MoonLake ImmunotherapeuticsMLTXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P25
Within normal range
vs 3Y Ago
-0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -4.00% |
| Q3 2025 | 22.17% |
| Q2 2025 | 34.45% |
| Q1 2025 | -9.66% |
| Q4 2024 | 13.04% |
| Q3 2024 | 50.89% |
| Q2 2024 | 81.82% |
| Q1 2024 | 60.71% |
| Q4 2023 | 6.76% |
| Q3 2023 | -12.85% |
| Q2 2023 | 17.38% |
| Q1 2023 | -34.78% |
| Q4 2022 | 25.98% |
| Q3 2022 | -20.84% |
| Q2 2022 | 9.04% |
| Q1 2022 | 109.51% |
| Q4 2021 | 645.32% |
| Q3 2021 | -97.76% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |